Group 1 - The China Securities Regulatory Commission (CSRC) has requested additional information from Lingke Pharmaceutical regarding its capital increases, share transfer pricing, compliance of shareholding changes, and the fairness of pricing for "sudden entry" shareholders [2][3] - Lingke Pharmaceutical, established in 2017, focuses on autoimmune and inflammatory diseases, planning to raise funds through its IPO for product development, office upgrades, research equipment procurement, and general corporate purposes [4] - The company's core pipeline revolves around the JAK-STAT signaling pathway, with key products including the second-generation JAK1 inhibitor LNK01001 and the third-generation pan-JAK inhibitor LNK01004, with plans to submit new drug applications between 2026 and 2027 [4] Group 2 - Lingke Pharmaceutical has raised over 1 billion yuan through five rounds of financing prior to its IPO submission, with a peak post-investment valuation of 3.422 billion yuan, backed by investors such as Eli Lilly Asia Fund and Junlian Capital [4] - The company reported minimal revenue primarily from bank interest and government subsidies, with other income of 21 million yuan, 17 million yuan, and 55 million yuan for the years 2023 to the first three quarters of 2025, alongside net losses of 260 million yuan, 312 million yuan, and 145 million yuan [4] - Lingke Pharmaceutical's cash flow from operating activities was negative, requiring external financing, with cash and cash equivalents dropping to 147 million yuan by the end of September 2025 [5] Group 3 - As of November 30, 2025, the largest shareholder group of Lingke Pharmaceutical controls 34.97% of the voting rights, with key figures including Wan Zhaokui as chairman and CEO, and Wang Jun as executive director and chief scientific officer [5] - Prior to the IPO submission, Lingke Pharmaceutical executed several share transfer transactions, resulting in a total cash-out of 20 million yuan [5]
凌科药业赴港上市备案进展更新 需补充说明股权转让价格等问题
Xi Niu Cai Jing·2026-01-19 10:02